Cantor Fitzgerald Downgrades Seattle Genetics (SGEN) to Sell
Get Alerts SGEN Hot Sheet
Price: $228.74 --0%
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 10
Rating Summary:
10 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 10
Join SI Premium – FREE
Cantor Fitzgerald downgraded Seattle Genetics (NASDAQ: SGEN) from Hold to Sell with a price target of $20.00 (from $30.00).
The firm comments, "Following a very successful launch that saw rapid acceptance, ADCETRIS has struggled to produce sequential quarterly growth, and that has been an issue for shareholders, keeping the shares largely range bound over the past few months. While we like the longer-term opportunity for ADCETRIS to become a much more significant revenue-generating product, the company's valuation relative to the near-term prospects no longer looks compelling to maintain our HOLD rating."
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $24.47 yesterday.
The firm comments, "Following a very successful launch that saw rapid acceptance, ADCETRIS has struggled to produce sequential quarterly growth, and that has been an issue for shareholders, keeping the shares largely range bound over the past few months. While we like the longer-term opportunity for ADCETRIS to become a much more significant revenue-generating product, the company's valuation relative to the near-term prospects no longer looks compelling to maintain our HOLD rating."
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $24.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Monness, Crespi, Hardt Downgrades Palantir Technologies Inc. (PLTR) to Sell on 'egregiously rich valuation... darkest days of this economic downturn are ahead of us'
- Cellectar Biosciences (CLRB) PT Raised to $12 at Oppenheimer
- Pool Corp (POOL) PT Raised to $436 at Oppenheimer, 'estimate POOL returns to adjusted EPS growth in 2024E'
Create E-mail Alert Related Categories
Analyst PT Change, Downgrades, Hot DowngradesRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!